Biotie to regain global rights to tozadenant from UCB

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 21, 2014 at 2:15 AM

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 21 March 2014 at 8.00 a.m. Biotie to regain global rights to tozadenant from UCB * Tozadenant is transitioning into Phase 3 development for Parkinson's disease * Biotie to host a conference call for analysts and media today at 14:00 Central European time Turku, Finland, March 21, 2014. Biotie Therapies Corp. announced today that UCB Pharma S.A. (UCB) will return global rights to tozadenant to Biotie. Tozadenant (SYN115), a selective inhibitor of the adenosine 2a (A2a) receptor, has delivered clinically relevant and statistically highly significant effects in Parkinson's disease, across multiple pre-specified evaluation parameters, in a 420 patient Phase 2b study completed in December 2012. Tozadenant is expected to start recruitment for the Phase 3 program in H1 2015. Biotie regaining the rights follows after UCB's assessment of its early and late stage clinical development pipeline as well as its preclinical opportunities and does not reflect any concerns regarding safety or efficacy of tozadenant. "We respect UCB's portfolio based decision, and appreciate its significant investment and commitment to the tozadenant program to-date. Owning full global rights to tozadenant will enable Biotie to evaluate the most suitable development strategy for this Phase 3 ready asset to maximize its value to our shareholders. As part of this evaluation we will consider other partners to assist us in the development and commercialization of this novel compound. We remain convinced that tozadenant will provide significant and clinically meaningful benefits to Parkinson's patients based on the robust and positive Phase 2b data, that we have already reported", says Timo Veromaa, President and CEO of Biotie. "At UCB, we have a very rich portfolio of research and development programs and continuously review and prioritize within the portfolio", says Prof. Dr. Iris Loew-Friedrich, CMO of UCB. "We will continue working with Biotie to make tozadenant phase 3 ready and to ensure a smooth transition of the program back to Biotie." UCB has confirmed that it will meet all its contractual and scientific commitments regarding the ongoing development program for tozadenant, including conducting together with Biotie the scheduled End-of-Phase 2 meeting with US Food and Drug Administration in H1 2014. The companies are working together to execute an appropriate transfer of the program back to Biotie. Tozadenant was originally licensed to UCB in 2010 and UCB paid Biotie $20 million to exercise its license in February 2013. Biotie expects to be able to give further guidance on any potential change in development timelines during Q2 2014. Turku, 21 March 2014 Biotie Therapies Corp. Timo Veromaa President and CEO Conference call An analyst and media conference call will take place on Friday, 21 March 2014 at 14:00 Central European Time, 15:00 Finnish Time. The conference call will be held in English. Lines are to be reserved ten minutes before the start of conference call. The event can also be viewed as a live webcast at www.biotie.com. An on demand version of the conference will be published on Biotie's website later during the day Telephone conference numbers: US callers: +1646 254 3362 UK callers: +44(0)20 3427 1906 Finnish callers: +358(0)9 6937 9590 Access code: 3535680 In case you need additional information or assistance, please contact: Virve Nurmi, IR Manager, Tel: +358 2 2748 911 For further information, please contact: Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, virve.nurmi@biotie.com David Dible, Citigate Dewe Rogerson Tel +44 207 282 2949, david.dible@citigatedr.co.uk Distribution: NASDAQ OMX Helsinki Ltd Main Media About tozadenant Tozadenant is an oral, potent and selective adenosine A2a receptor antagonist being developed for the treatment of Parkinson's disease. Tozadenant has displayed clinically relevant and statistically highly significant effects in Parkinson's disease, across multiple pre-specified evaluation metrics, in a 420 patient Phase 2b study completed in December 2012, and it is currently transitioning into Phase 3 development. The preparations for the tozadenant Phase 3 program in Parkinson's disease have progressed well. These activities include CMC and non-clinical work, and certain Phase 3 enabling clinical pharmacology studies. About Biotie Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. For the past years, Biotie has successfully operated a strategy built around search, profile and partner. This has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in February 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S, and tozadenant, a novel A2a antagonist which is transitioning into Phase 3 development for Parkinson's disease and for which Biotie holds exclusive, global rights. Biotie is actively developing its pipeline assets, including SYN120, a unique potent 5-HT6/5-HT2a dual antagonist for which a Phase 2 study in Alzheimer's diseases is expected to commence recruitment by the end of 2014; nepicastat, a selective inhibitor of dopamine beta hydroxylase which is currently in a Phase 2 study, fully funded by NIDA, for treatment seeking cocaine addicts and for which topline data is expected in the first half of 2015; and BTT-1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 for which a Phase 2 study in primary sclerosing cholangitis, a rare fibrotic disease of the liver, is expected to start recruiting by the end of 2014. Biotie's shares are listed on NASDAQ OMX Helsinki. www.biotie.com [HUG#1770564]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cboe Global Hits Record Index Options Volume in October

October's Market Landscape: Peaks and Troughs Sometimes you look at market reports and it feels like you're staring at a rollercoaster's wild ride. This past October was a month full of twists for Cboe Global Markets, Inc. (Cboe: CBOE). With trading volumes shifting dramatically across its various segments, Cboe delivered some impressive highlights against a mixed...

MY DR NOW Expands: Seven-Day Clinics Open Everywhere

Breaking The Mold Of Traditional Medicine MY DR NOW isn't here to play by the age-old rules. They're slinging open the doors to their newest family medicine clinics and kicking the old Monday-to-Friday scheduling straight to the curb. Every single day of the week, from 8 a.m. to 8 p.m., patients in Sunnyvale and Tucson are getting a dose of healthcare that's all about...

Zillow Eases the FHA Down Payment Burden

A New Financial Lifeline for Homebuyers In a market where finding a foothold in the housing game feels like scaling Everest without ropes, Zillow Home Loans has tossed a lifeline to potential homeowners. Their latest move might just be what many house hunters needed to hear—offering a hand where it’s been missing for years: down payment assistance for FHA loans. The...

Elite Academy Takes Bold Step in Ethical AI for Schools

Pioneering New Fronts in Education with AI Elite Academic Academy, a stalwart in California's public charter school landscape, has just taken a significant stride forward by stepping into the EDSAFE AI Alliance District Policy Lab. The move, announced in early November 2026, sees Elite diving into the intricate world of artificial intelligence in education, with a pointed...

WellNet Embraces Voice AI for Provider Calls

Ever met a TPA grappling over their provider call costs like a crusty sailor with a rusted anchor? Welcome to WellNet Healthcare, folks. They've tapped EHVAhealth's conversational voice AI to take a solid swing at automating those burdensome provider calls. They're no stranger to the chaos of managing member eligibility and benefits verification, and this move might just...

Hidden Costs of Lineworker and CDL Training in California

The True Financial Picture of Skilled Trade Programs Ever wonder why that flashy tuition number doesn't line up with your wallet by the end of your training days? That's the reality smashing aspiring lineworkers and future truck drivers in Northern California right in the face. We're talking about a full breakdown here, beyond what the glossy brochures ever tell you....

Fedora and Clarion Boost Oncology Practice Performance

Hell of a Pair-Up: Fedora and Clarion Focus on Oncology Well, here's a setup that doesn't scream about blue chip stocks—but it's swimming in opportunity all the same. Fedora Healthcare Solutions just shook hands with Clarion, cementing a deal that's piqued my interest for its potential to green-light some real progress for independent oncology practices. These are not...

Exiger Lands $12M Deal with USAF for ICBM Insights

Exiger's New Partnership: A $12M Heavyweight Move The Air Force isn’t about to let its guard down when it comes to those intercontinental ballistic missiles. Nope, the powers that be have decided it’s time to pump some serious dough into the chain that keeps those missiles ready to go, handing $12 million over to Exiger to light the path through the complex web of the...

Class Action Targets Extremist Groups, Interference

Legal Spar on the Horizon: Class Action Commences The legal world now sees a fresh duel as Impresa Legal Group rolls up its sleeves and files a class action lawsuit against certain extremist groups and foreign-funded entities. At the heart of this legal action are accusations that these outfits have orchestrated a campaign to intimidate data center workers while meddling...

Centrus Energy's Quarter Ups and Downs Unpacked

Stirring the Pot: Centrus Energy's Rollercoaster Quarter Trading never fails to serve up surprises, and Centrus Energy Corp. (NYSE:LEU) is dishing them out this quarter. Despite a revenue slip to $55.5 million from last year’s $74.9 million, GAAP net income rocketed to a whopping $31.6 million. Talk about a mixed bag of fortunes. Diving Deeper into the Numbers Revenue...